1. Medtech Insight

Pandemic ‘Dividend’ Must Not Be Squandered

Diagnostics Companies Press For Higher Priority Status For Data Sharing And Access To Testing

 
• By Ashley Yeo

Maintaining the positive changes that health care delivery underwent at the height of COVID-19 has been the talk of the health care industries, but will commercial organizations retain their enthusiasm once the pressures of the pandemic abate?

Light bulb idea.

The shock of COVID-19 led many device and diagnostics companies to pivot, rapidly and successfully, to a response mode and then to medium-term coping mechanisms. They learnt much about the inadequacies of even mature health care systems to respond to an extreme public health emergency. Some were confronted with shortcomings of their own.

Many stressed the need for longer-term health care delivery planning and better cross-border collaboration. Excess capacity should be built into health care systems in readiness for similar events in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.